PCV29 PHARMACOECONOMIC ANALYSIS OF EXTENDED PROPHYLAXIS BY ENOXAPARIN AFTER HIP JOINT REPLACEMENT
Lomakin A, Kulikov A Moscow Medical Academy, Moscow, Russia OBJECTIVES: Pharmacoeconomic analysis of extended preventive injection of enoxaparin after hip joint replacement and costing of one prevented case of deep venous thrombosis (DVT) in the enoxaparin group compared to placebo in Russia.
METHODS:
The pharmacoeconomic analysis was based on the results of prospective, randomized, double controlled study of the use of enoxaparin as extended DVT prophylaxis conducted in a clinical center in Sweden (Bergqvist D. et al., 1996) . The efficiency of extended prophylaxis by enoxaparin versus placebo in hospital environment was studied during the trial. All patients (n = 262) received a daily hypodermic injection of 40 mg of enoxaparin after preventative hip joint replacement, on average during 9 days of their hospitalization (open study period). After that the patients were randomized in groups. 131 patients in the placebo group and 131 patients in the enoxaparin group received the treatment. It was suggested that the patients of both groups be injected with 40 mg of enoxaparin daily, on average during 18.6 days. In the clinical trial the number of detected DVT in each group was assumed as the most adequate index of efficiency. 21 and 45 DVT cases were detected in the enoxaparin and the placebo group respectively. RESULTS: In Russia total costs of extended prophylaxis after hip joint replacement in comparison groups amounted to $186,272 in the enoxaparin group and $159,584 in the placebo group. Costs per patient amounted to $1422 in the enoxaparin group and to $1218 in the placebo group. With the help of efficiency increment analysis, the cost of one DVT case prevented by way of extended prophylaxis by enoxaparin versus placebo amounted to $1112. CONCLU-SION: According to the results of the pharmacoeconomic analysis based on the findings of the clinical trial, the cost of one DVT case prevented with the help of extended prophylaxis by enoxaparin versus placebo is $1112. Given the changing statin marketplace, this study compares the cost-effectiveness among generic statins (lovastatin, pravastatin, simvastatin) and more effective branded monotherapy statins (atorvastatin, rosuvastatin) for first and second tier placement consideration, respectively, in routine clinical practice. METHODS: Retrospective electronic medical record database study was conducted of newly prescribed statin therapy during August 2003-March 2005. Effectiveness of each statin in reducing LDL-C and attaining National Cholesterol Education Panel Adult Treatment Panel III LDL-C goal was evaluated using multivariate regressions after adjusting for baseline LDL-C, demographics, comorbidities, and therapy duration. Cost-effectiveness from a payer perspective was estimated for rosuvastatin and atorvastatin (branded statins), and separately for lovastatin, simvastatin and pravastatin (generic statins). Annualized costs for statin (wholesale acquisition cost, WAC) and titration were included. RESULTS: Of 10,421 eligible patients, adjusted LDL-C reduction was significantly greater (p < 0.001) with rosuvastatin (−31.6%) than atorvastatin (−21.9%) and other generic statins (−19.1% to −13.9%). Average dose of rosuvastatin was 12 mg vs. 17-35 mg for other statins. Among patients not at goal at baseline, the adjusted percentage of moderate/high risk patients attaining LDL-C goal was higher (p < 0.001) for rosuvastatin (76.1%) versus atorvastatin (72.6%) and other statins (57.6%-65%). Rosuvastatin was more effective and less costly than atorvastatin in terms of cost per patient reaching goal (in high and moderate risk patients) and in terms of percent LDL-C lowering. Simvastatin and pravastatin required a discount greater than 61% and 71%, respectively, from the branded WAC to achieve cost per unit of LDL-C reduction lower than generic lovastatin. CONCLUSION: To facilitate effective and efficient management of patients with dyslipidemia, a tiered formulary could include generic simvastatin or pravastatin as the cost-effective generic statin in the first tier (depending upon level of discount to current WAC) and rosuvastatin as the cost-effective branded statin in the second tier. Clinical evidence suggests that achieving recommended HDL-C levels reduces the likelihood of CHD events and mortality. The benefits of standard fenofibrate formulation on HDL-C and triglyceride levels (TG) are well established; however, full benefits have typically required administration with food. Furthermore, evidence suggests that as many as 30% of people do not comply with food requirements. A new formulation of fenofibrate (fenofibrate 145) that does not require administration with food has been developed. A cost-effectiveness model was developed to determine the incremental cost of meeting additional recommended lipid levels when fenofibrate 145 is substituted for a standard fenofibrate formulation that requires food administration in a diabetic population. METHODS: A simulation model using a managed care perspective was designed to predict changes in lipid levels [HDL-C, LDL-C, TG, and total cholesterol (TC)] and associated drug costs based on Wholesale Acquisition Costs over the course of 1 year. Lipid targets were based on NCEP-ATP III. A hypothetical cohort of 1000 was modeled for a diabetic population with abnormal lipid levels based on NHANES data. Lipid changes were based on the study of fenofibrate by Athyros, et al. 2002 . A reduction in efficacy for each lipid parameter, based on previously reported work, was applied against patients on standard fenofibrate therapy (requiring food co-administration). RESULTS: In a cohort of 1000 patients, substituting fenofibrate 145 for standard fenofibrate therapy resulted in 9.4% more diabetic patients reaching TG targets. Seventy-two more patients (11% increase) on fenofibrate 145 achieved at least 2 targets and 27 more patients (18% increase) achieved at least 3 targets. The incremental 1 year cost per additional patient reaching TG targets was $0.78. CONCLUSION: Substituting a non-food requiring fenofibrate for a standard fenofibrate increases the number of patients achieving TG and multiple target goals at 1 year at a low cost.
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PCV32 IMPACT OF DEPRESSION ON HEALTH STATUS AND HEALTH CARE UTILIZATION IN PATIENTS WITH HYPERTENSION: RESULTS FROM THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS 2002-2003)
Shi L, Liao EK, Khan M Tulane University, New Orleans, LA, USA OBJECTIVES: Previous studies have examined the association between depression and hypertension. This study aims to examine whether health status and health care costs differ between hypertensive patients with and without depression.
METHODS:
The study sample was all adult survey respondents with a self-reported diagnosis of hypertension from the MEPS (2002) (2003) . These respondents were also asked about the presence of conditions related to depression. Health status measures include SF-12 physical component summary (PCS) and SF-12 mental component summary (MCS) score, and EQ-5D utility score. Health care utilization was explored in the following categories: outpatient, inpatient, dental, and pharmacy. The impact of depression on health status or health care utilization was explored using multivariate linear regression models with depression as an independent dummy variable, after controlling for age, gender, ethnicity, marital status, income, and health insurance. All analyses are weighted to the US population by the personal level weights reported in the MEPS data set. RESULTS: Among a total of 5052 MEPS respondents having hypertension, 1962 reported having (38.84%) depression problems. These two groups (with and without depression) were comparable in age and ethnicity. Female hypertensive patients with lower income level or with Medicare or Medicaid coverage had a higher proportion of depression. In regression models, hypertensive patients with depression had worse health status: SF-12 PCS score (−5.6, p < 0.0001), SF-12 MCS score (−13.5, p < 0.0001), and EQ-5D utility score (−0.20, p < 0.0001). Hypertensive patients with depression had higher utilization of outpatient ($415, p < 0.0001) and pharmacy ($10, p < 0.0001) services, but both groups had comparable expenditures in inpatient care ($0.09, p < 0.0001) and dental service (−$23, p > 0.05). CON-CLUSION: In the U.S. population, hypertensive patients with depression had poorer health status and higher health care expenditure in outpatient services and prescription drug compared with those without depression. The difference in inpatient cost between these groups was very small. 2003-6/2006 (n = 47,364) . All medical and pharmacy claims were analyzed during this period. Analysis focused on outpatient use patterns of clopidogrel and patient characteristics, e.g., demographics, comorbidities, inpatient history, and other cardiovascular medication use. Aspirin therapy was not available in the prescription claims data. RESULTS: Clopidogrel was the most widely prescribed antiplatelet, representing 93% of all prescriptions. Men represented 65% of the patients taking clopidogrel. The mean age was 56.9 years, with 69% of individuals aged 50 to 65 years. The most common outpatient diagnoses were essential hypertension (61%), unspecified hyperlipidemia (57%), hypercholesterolemia (44%), and unspecified chest pain (43%). On average, users of clopidogrel had 3.41 prescriptions per month in 2006 at a health plan cost of $376.50/month. Average length of therapy for clopidogrel was 292 days. By patient type, it varied from 283 days for coronary artery bypass surgery, 336 days for percutaneous coronary intervention (PCI), and 344 days for stroke. However, 10.4% of PCI patients took clopidogrel for ≤30 days. Patients refilled their clopidogrel prescriptions for 93% of the daily regimen needed during therapy. Frequent concomitant cardiac medications included statins (63.9%), beta-blockers (55.0%), ACE-inhibitors (48.7%), and diuretics (14.2%). Data show that 40-50% of patients discontinued another concomitant cardiac
PCV33 ANALYSIS OF CLOPIDOGREL USE IN OUTPATIENT SETTINGS
